Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Mortality Risk Factors Among People Living with HIV Receiving Second-line Antiretroviral Therapy in Rural China

Author(s): Qiujia Kang, Wanqi Pan, Yanmin Ma, Dongli Wang, Huangchao Jia, Huijun Guo, Feng Sang, Liran Xu, Qianlei Xu* and Yantao Jin*

Volume 22, Issue 2, 2024

Published on: 19 January, 2024

Page: [100 - 108] Pages: 9

DOI: 10.2174/011570162X280721240108065502

Price: $65

conference banner
Abstract

Background: Second-line antiretroviral therapy (ART) was introduced in Henan Province in 2009. The number of people living with human immunodeficiency virus (HIV) starting this therapy is increasing.

Objective: This study aimed to investigate the survival and factors affecting mortality among this group.

Methods: We conducted a retrospective cohort study of people living with HIV (PLHIV) who switched to second-line ART between May 1, 2010, and May 1, 2016, using the Kaplan–Meier method and Cox proportional hazards models.

Results: We followed 3,331 PLHIV for 26,988 person-years, of whom 508 (15.3%) died. The mortality rate was 1.88/100 person-years. After adjusting for confounding factors, we found being a woman (hazard ratio (HR), 0.66; 95% confidence interval (CI) 0.55–0.79), > 50 years old (HR, 2.69; 95% CI, 2.03–3.56), single/widowed (HR, 1.26; 95% CI, 1.04–1.52), having > 6 years of education (HR, 0.78; 95% CI, 0.65–0.94), Chinese medicine (HR, 0.75; 95% CI, 0.52–0.96), liver injury (HR, 1.58; 95% CI, 1.19–2.10), and CD4+ T cell count <200 cells/μl (HR, 1.94; 95% CI, 1.47-2.55), or 200-350 cells/μl (HR, 1.37; 95% CI, 1.03–1.82) were associated with mortality risk.

Conclusions: We found lower mortality among PLHIV who switched to second-line ART than most previous studies. The limitations of a retrospective cohort may, therefore, have biased the data, and prospective studies are needed to confirm the results. Moreover, Chinese medicine combined with second-line ART shows potential as a treatment for HIV.

Next »
Graphical Abstract

[1]
Unaids. Global AIDS update. 2020. Available from: https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf
[2]
Barik SK, Bansal AK, Mohanty PS, et al. Detection of drug resistance mutations in the reverse transcriptase gene of hiv-1-infected north indian population failing first-line antiretroviral therapy “a follow-up cohort study”. AIDS Res Hum Retroviruses 2021; 37(10): 796-805.
[http://dx.doi.org/10.1089/aid.2020.0132] [PMID: 33390085]
[3]
Alene M, Awoke T, Yenit MK, Tsegaye AT, Yismaw L, Yeshambel R. Second-line antiretroviral therapy regimen change among adults living with HIV in Amhara region: a multi-centered retrospective follow-up study. BMC Res Notes 2019; 12(1): 407.
[http://dx.doi.org/10.1186/s13104-019-4429-3] [PMID: 31307513]
[4]
Martinez-Vega R, De La Mata NL, Kumarasamy N, et al. Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE). Antivir Ther 2018; 23(2): 167-78.
[http://dx.doi.org/10.3851/IMP3194] [PMID: 28933705]
[5]
Sam M, Masaba JPM, Alio D, Byakika-Tusiime J. Treatment failure and associated factors among individuals on second line antiretroviral therapy in Eastern Uganda: A retrospective cohort study. Infect Dis 2021; 14(1786337211014518)
[http://dx.doi.org/10.1177/11786337211014518] [PMID: 34121842]
[6]
Edessa D, Sisay M, Asefa F. Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One 2019; 14(7): e0220159.
[http://dx.doi.org/10.1371/journal.pone.0220159] [PMID: 31356613]
[7]
Zenebe Haftu A, Desta AA, Bezabih NM, et al. Incidence and factors associated with treatment failure among HIV infected adolescent and adult patients on second-line antiretroviral therapy in public hospitals of Northern Ethiopia: Multicenter retrospective study. PLoS One 2020; 15(9): e0239191.
[http://dx.doi.org/10.1371/journal.pone.0239191] [PMID: 32986756]
[8]
WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV Infection: Recommendations for a public health approach. 2013. Available from : https://www.who.int/publications/i/item/9789241549684
[9]
Development of china free art manual. Available from: http://www.aizhi.org/UploadSoft/2005321103838886.pdf
[10]
Gao L, Xia H, Zeng R, et al. Pre-treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China. HIV Med 2022; 23(S1) (Suppl. 1): 84-94.
[http://dx.doi.org/10.1111/hiv.13252] [PMID: 35293099]
[11]
Chen J, Zhang M, Shang M, Yang W, Wang Z, Shang H. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China. BMC Infect Dis 2018; 18(1): 571.
[http://dx.doi.org/10.1186/s12879-018-3489-7] [PMID: 30442114]
[12]
Dou Z, Chen RY, Wang Z, et al. HIV-infected former plasma donors in rural central china: From infection to survival outcomes, 1985-2008. PLoS One 2010; 5(10): e13737.
[http://dx.doi.org/10.1371/journal.pone.0013737] [PMID: 21060835]
[13]
Zhang F, Wang Y, Wang J. Handbook of China's free ART program. Cell Research 2012; 15: 877-82.
[14]
Xu Q, Guo H, Jin Y, et al. Advantages of chinese medicine for patients with acquired immunodeficiency syndrome in rural central china. Chin J Integr Med 2018; 24(12): 891-6.
[http://dx.doi.org/10.1007/s11655-017-2418-8] [PMID: 28887810]
[15]
Jin Y, Zhang M, Ma Y, et al. Effects of chinese medicine on the survival of aids patients administered second-line ART in rural areas of china: A retrospective cohort study based on real-world data. Evid Based Complement Alternat Med 2022; 2022: 5103768.
[http://dx.doi.org/10.1155/2022/5103768]
[16]
Jin Y, Meng X, Liu S, et al. Prevalence trend and risk factors for anemia among patients with human immunodeficiency virus infection receiving antiretroviral therapy in rural China. J Tradit Chin Med 2019; 39(1): 111-7.
[17]
Liang Y, Yang W J, Sun D Y, et al. [Survival analysis on former plasma donors living with HIV/AIDS after initiation of antiretroviral therapy in Henan province. Zhonghua Liu Xing Bing Xue Za Zhi 2019; 40(6): 638-42.
[http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2019.06.007]
[18]
Zhu J, Gao R, Zhao S, et al. Chinese guidelines for prevention and treatment of dyslipidemia in adults (2016 Revision). Chin J Circulat 2016; 31(10): 937-53.
[19]
Tsung I, Dolan R, Lao CD, et al. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Aliment Pharmacol Ther 2019; 50(7): 800-8.
[http://dx.doi.org/10.1111/apt.15413] [PMID: 31309615]
[20]
Hematology Branch of Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia (2022 edition). Chin Med J 2022; 102(41): 3246-56. [J].
[http://dx.doi.org/10.3760/cma.j.cn112137-20220621-01361]
[21]
Cao W J, Yao Y M, Wei W, et al. [Survival time and related factors on HIV/AIDS patients in Guizhou province from 1995 to 2018. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41(4): 557-61.
[http://dx.doi.org/10.3760/cma.j.cn112338-20190604-00395]
[22]
Tsegaye AT, Alemu W, Ayele TA. Incidence and determinants of mortality among adult HIV infected patients on second-line antiretroviral treatment in Amhara region, Ethiopia: a retrospective follow up study. Pan Afr Med J 2019; 33: 89.
[http://dx.doi.org/10.11604/pamj.2019.33.89.16626] [PMID: 31489067]
[23]
Gao D, Zou Z, Dong B, et al. Secular trends in HIV/AIDS mortality in China from 1990 to 2016: Gender disparities. PLoS One 2019; 14(7): e0219689.
[http://dx.doi.org/10.1371/journal.pone.0219689] [PMID: 31318900]
[24]
Mangal TD, Meireles MV, Pascom ARP, de Almeida Coelho R, Benzaken AS, Hallett TB. Determinants of survival of people living with HIV/AIDS on antiretroviral therapy in Brazil 2006–2015. BMC Infect Dis 2019; 19(1): 206.
[http://dx.doi.org/10.1186/s12879-019-3844-3] [PMID: 30819120]
[25]
Zhu K, Xu Q, Ma Y, et al. Suboptimal immune recovery and associated factors among people living with HIV/AIDS on second-line antiretroviral therapy in central China: A retrospective cohort study. J Med Virol 2022; 94(10): 4975-82.
[http://dx.doi.org/10.1002/jmv.27944] [PMID: 35710693]
[26]
Ahn MY, Jiamsakul A, Khusuwan S, et al. The influence of age-associated comorbidities on responses to combination antiretroviral therapy in older people living with HIV. J Int AIDS Soc 2019; 22(2): e25228.
[http://dx.doi.org/10.1002/jia2.25228] [PMID: 30803162]
[27]
Ross J, Jiamsakul A, Kumarasamy N, et al. Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific. HIV Med 2020; 22(3): 201-11.
[http://dx.doi.org/10.1111/hiv.13006] [PMID: 33151020]
[28]
Marchionatti A, Parisi MM. Anemia and thrombocytopenia in people living with HIV/AIDS: A narrative literature review. Int Health 2021; 13(2): 98-109.
[http://dx.doi.org/10.1093/inthealth/ihaa036] [PMID: 32623456]
[29]
Deressa T, Damtie D, Workineh M, Genetu M, Melku M. Anemia and thrombocytopenia in the cohort of HIV-infected adults in northwest Ethiopia: A facility-based cross-sectional study. EJIFCC 2018; 29(1): 36-47.
[PMID: 29765285]
[30]
Nigussie F, Alamer A, Mengistu Z, Tachbele E. Survival and predictors of mortality among adult HIV/AIDS patients initiating highly active antiretroviral therapy in debre-berhan referral hospital, amhara, ethiopia: A retrospective study. HIV AIDS 2020; 12: 757-68.
[http://dx.doi.org/10.2147/HIV.S274747] [PMID: 33239921]
[31]
Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol 2017; 2(3): 211-23.
[http://dx.doi.org/10.1016/S2468-1253(16)30120-0] [PMID: 28404136]
[32]
Taborelli M, Suligoi B, Toffolutti F, et al. Excess liver-related mortality among people with AIDS compared to the general population: An Italian nationwide cohort study using multiple causes of death. HIV Med 2020; 21(10): 642-9.
[http://dx.doi.org/10.1111/hiv.12937] [PMID: 32876382]
[33]
Jin Y, Wang X, Li Z, et al. Survival of AIDS patients treated with traditional chinese medicine in rural central china: A retrospective cohort study, 2004-2012. Evid Based Complement Alternat Med 2015; 2015: 1-7.
[http://dx.doi.org/10.1155/2015/282819] [PMID: 25821482]
[34]
Wang Y, Jin F, Wang Q, et al. Long-term survival of AIDS patients treated with only traditional chinese medicine. Altern Complement Ther 2017; 23(2): 60-2.
[http://dx.doi.org/10.1089/act.2017.29106.ywa]
[35]
Li X, Li H, Li C, Xia W, Li A, Li W. Traditional chinese medicine can improve the immune reconstruction of HIV/AIDS patients. AIDS Res Hum Retroviruses 2020; 36(4): 258-9.
[http://dx.doi.org/10.1089/aid.2019.0274] [PMID: 31958968]
[36]
Wang D, Ma S, Ma Y, et al. Effect of traditional chinese medicine therapy on the trend in CD4+ T-Cell counts among patients with HIV/AIDS treated with antiretroviral therapy: A retrospective cohort study. Evid Based Complement Alternat Med 2021; 2021: 5576612.
[http://dx.doi.org/10.1155/2021/5576612]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy